Medical Pharmacology: Chapter 19: Anti-Seizure Drug Pharmacology -- Module 5: Ethosuximide, Newer Anti-Seizure Drugs, and Adjunctive Agents

Chapter 19: Anti-Seizure Drug Pharmacology — Module 5: Ethosuximide, Newer Anti-Seizure Drugs, and Adjunctive Agents
Tier: Tier 3 — Clinical Vignette (11 questions)

1. An 8-year-old girl with childhood absence epilepsy (CAE) has been well-controlled on ethosuximide 500 mg/day for 18 months with absence seizures fully suppressed and plasma levels consistently in the therapeutic range. She now presents after her first witnessed generalized tonic-clonic seizure (GTCS) during sleep. Her EEG shows generalized spike-and-wave discharges. Neurological examination is normal. Which change to her anti-seizure regimen is most appropriate?

A) Increase ethosuximide to the maximum tolerated dose and add levetiracetam as adjunctive therapy for the GTCS component, because this combination targets both the thalamo-cortical oscillation and cortical hyperexcitability through complementary mechanisms without the metabolic risks of valproate in a child
B) Discontinue ethosuximide and initiate lamotrigine monotherapy, because lamotrigine covers both absence seizures and generalized tonic-clonic seizures and avoids the gastrointestinal adverse effects and hiccups associated with continued ethosuximide use in this age group
C) Transition to valproate monotherapy or add valproate to the current ethosuximide regimen, because ethosuximide has no efficacy against generalized tonic-clonic seizures and valproate is the established broad-spectrum agent effective against both absence seizures and GTCSs in this clinical context
D) Continue ethosuximide unchanged and add a low-dose benzodiazepine such as clonazepam for GTCS coverage, because benzodiazepines provide rapid broad-spectrum anti-seizure activity and are well tolerated as long-term adjuncts in children with generalized epilepsy syndromes
E) Discontinue ethosuximide and initiate topiramate monotherapy, because topiramate is FDA-approved for primary generalized tonic-clonic seizures as monotherapy and its broad mechanism of action including sodium channel blockade and GABA enhancement provides superior coverage of both seizure types compared to ethosuximide

ANSWER: C

Rationale:

Ethosuximide's anti-seizure efficacy is mechanistically limited to absence seizures that depend on T-type calcium channel-driven thalamo-cortical oscillation. It has no established efficacy against generalized tonic-clonic seizures, which arise through different mechanisms involving widespread cortical hyperexcitability. The emergence of GTCSs in a child with CAE is a well-recognized clinical transition that changes the treatment target: the drug regimen must now cover both seizure types. Valproate is the appropriate choice in this setting because it is a broad-spectrum agent effective against both absence seizures and GTCSs, and it is the standard drug for epilepsy syndromes where both types coexist. The practical approach is either to switch from ethosuximide to valproate monotherapy or to add valproate while tapering ethosuximide, depending on clinical circumstances.

Option A: Option A is incorrect because ethosuximide at any dose has no efficacy against GTCSs, and increasing its dose will not address the new seizure type; levetiracetam is a reasonable GTCS adjunct but the failure to address ethosuximide's fundamental lack of GTCS coverage makes this option incomplete as a primary strategy.
Option B: Option B is incorrect because lamotrigine performed substantially worse than both ethosuximide and valproate for absence seizure suppression in the CAE trial (29% seizure freedom versus approximately 53–58%), making it a second-line rather than first-line choice when transitioning from ethosuximide; valproate is the established broad-spectrum first-line agent for this transition.
Option D: Option D is incorrect because chronic benzodiazepine use in children for GTCS control is not a standard long-term management strategy; tolerance develops to benzodiazepine anti-seizure effects, and benzodiazepines are not recommended as maintenance therapy for generalized epilepsy syndromes.
Option E: Option E is incorrect because while topiramate has broad-spectrum activity, it is not the established first-line agent for transitioning a child with CAE who develops GTCSs; valproate is the standard of care for this clinical scenario, and topiramate's cognitive adverse effects and metabolic effects in children make it a less favorable first-line choice than valproate in this context.

2. A 34-year-old man with drug-resistant focal epilepsy has been stable on phenytoin 300 mg/day with a plasma level of 14 mcg/mL for two years. Cenobamate 12.5 mg/day is initiated and titrated per the mandatory slow schedule. Eight weeks into titration, now at cenobamate 50 mg/day, he develops nystagmus, ataxia, and confusion. His phenytoin level is 28 mcg/mL — double the baseline despite no change in phenytoin dose. Which explanation and management step are correct?

A) Cenobamate has induced CYP3A4, which paradoxically increases phenytoin conversion to a toxic epoxide metabolite that accumulates because phenytoin's epoxide hydrolase is slower than cenobamate's production rate; the phenytoin dose should be increased to compensate for the reduced parent drug levels that will follow
B) Cenobamate has displaced phenytoin from plasma albumin binding, doubling the free phenytoin fraction while the total level rises artifactually due to increased tissue release of stored phenytoin; free phenytoin measurement will confirm normal free drug exposure and no dose change is needed
C) Cenobamate has inhibited the renal tubular transporter responsible for phenytoin excretion, reducing its elimination and causing accumulation; phenytoin should be switched to a renally-cleared anti-seizure drug to avoid further interaction with cenobamate's transporter effects
D) Cenobamate has saturated phenytoin's zero-order elimination kinetics by competing for the same CYP2C9 binding site, causing phenytoin to accumulate disproportionately; the correct management is to reduce cenobamate to the lowest effective dose so that CYP2C9 competition is minimized
E) Cenobamate inhibits CYP2C9 and CYP2C19, the primary enzymes responsible for phenytoin metabolism; reduced clearance at even low cenobamate doses has doubled phenytoin plasma concentrations, producing classic phenytoin toxicity; the phenytoin dose should be reduced by approximately 50% per prescribing guidance, and levels monitored closely as cenobamate titration continues

ANSWER: E

Rationale:

Phenytoin is metabolized primarily by CYP2C9 with a secondary CYP2C19 contribution. Cenobamate inhibits CYP2C19 even at lower doses during titration and has complex dose-dependent effects on CYP2C9. The U.S. prescribing information for cenobamate specifically recommends reducing phenytoin or phenobarbital doses by approximately 50% when cenobamate is initiated, anticipating this interaction. Phenytoin's pharmacokinetics operate at zero-order (capacity-limited) kinetics at therapeutic concentrations, meaning that even modest reductions in its metabolic clearance produce disproportionately large rises in plasma concentration — a small reduction in CYP2C9 activity can double or triple the plasma level. This patient's presentation of nystagmus, ataxia, and confusion at a phenytoin level of 28 mcg/mL is classic phenytoin toxicity from accumulation. The correct immediate action is to reduce the phenytoin dose substantially — approximately 50% per label guidance — and to monitor levels closely as cenobamate titration continues upward, since higher cenobamate doses have additional CYP effects.

Option A: Option A is incorrect because cenobamate induces rather than inhibits CYP3A4, and phenytoin does not accumulate through an epoxide pathway analogous to carbamazepine; phenytoin's primary toxic metabolite concern is the arene oxide, but the clinical interaction described here is CYP2C9/2C19 inhibition causing parent drug accumulation, not an epoxide-mediated mechanism.
Option B: Option B is incorrect because phenytoin is approximately 90% protein-bound and displacement can contribute to free drug elevation, but a doubling of total phenytoin level cannot be explained by protein displacement alone — that mechanism would increase the free fraction while leaving total level unchanged or slightly reduced; the total level rise here reflects reduced metabolic clearance from CYP inhibition.
Option C: Option C is incorrect because phenytoin is not significantly eliminated by renal tubular transport; it is metabolized hepatically to an inactive hydroxylated metabolite and the interaction is metabolic, not renal.
Option D: Option D is incorrect because while both drugs may use CYP2C9, cenobamate's clinical effect is inhibition of phenytoin's CYP2C9-mediated metabolism rather than simple competitive saturation; reducing cenobamate to minimize competition is not the clinical management strategy — the correct action is to reduce the phenytoin dose per prescribing guidance.

3. A 29-year-old woman with drug-resistant focal epilepsy is on carbamazepine (CBZ) 600 mg twice daily and levetiracetam 1500 mg twice daily. Seizures are controlled but she has persistent irritability, mood instability, and interpersonal difficulties that her neurologist attributes to levetiracetam's psychiatric adverse effects. The decision is made to switch from levetiracetam to brivaracetam. Which monitoring consideration is specifically introduced by this switch and was not a concern while the patient was on levetiracetam?

A) After switching to brivaracetam, the patient should be monitored for signs of carbamazepine toxicity — diplopia, dizziness, nausea, ataxia — even if total CBZ plasma levels remain within the therapeutic range, because brivaracetam inhibits epoxide hydrolase and can cause carbamazepine-10,11-epoxide to accumulate to toxic concentrations that standard CBZ assays do not detect
B) After switching to brivaracetam, the patient requires monthly complete blood counts for the first year because brivaracetam's amidase metabolic pathway produces a reactive intermediate that can cause dose-dependent bone marrow suppression not associated with levetiracetam's renal elimination pathway
C) After switching to brivaracetam, the patient's carbamazepine dose should be reduced by 30% preemptively because brivaracetam inhibits CYP3A4, the primary enzyme responsible for carbamazepine metabolism, and unmanaged inhibition will cause CBZ parent drug to accumulate to supratherapeutic levels within two weeks
D) After switching to brivaracetam, renal function must be monitored monthly because unlike levetiracetam — which is renally eliminated and therefore familiar to clinicians in terms of renal dosing — brivaracetam undergoes renal metabolism of its carboxylic acid metabolite that can accumulate and cause nephrotoxicity in patients with even mild renal impairment
E) After switching to brivaracetam, the patient should have her hepatic function tests checked at baseline because levetiracetam does not affect the liver while brivaracetam's CYP2C19-mediated metabolism produces a hepatotoxic intermediate metabolite; however, no dose adjustment is needed unless ALT rises above five times the upper limit of normal

ANSWER: A

Rationale:

The specific monitoring concern introduced by switching from levetiracetam to brivaracetam in a patient also taking carbamazepine is the risk of carbamazepine-10,11-epoxide accumulation. Levetiracetam does not inhibit epoxide hydrolase and therefore does not affect CBZ epoxide metabolism. Brivaracetam, however, is a weak inhibitor of epoxide hydrolase — the enzyme that converts the active CBZ-10,11-epoxide to its inactive trans-diol. When this conversion is slowed, the epoxide accumulates even while total CBZ parent drug levels remain within the standard therapeutic range, because standard CBZ assays do not measure the epoxide. CBZ-10,11-epoxide contributes to the neurotoxic adverse effects of carbamazepine — diplopia, dizziness, nausea, ataxia — and toxicity can occur at normal total CBZ levels when the epoxide fraction rises. This interaction was absent during the levetiracetam phase and is specifically introduced by the switch to brivaracetam, making it the correct answer to this question about what is new after the switch.

Option B: Option B is incorrect because brivaracetam's amidase metabolic pathway does not produce a bone marrow-toxic reactive intermediate; bone marrow suppression is a rare idiosyncratic concern for drugs such as carbamazepine and felbamate, not a mechanism-based concern for brivaracetam.
Option C: Option C is incorrect because brivaracetam does not inhibit CYP3A4; it is metabolized primarily by amidase hydrolysis and does not meaningfully affect CYP3A4-mediated carbamazepine metabolism. A preemptive 30% carbamazepine dose reduction is not indicated when starting brivaracetam.
Option D: Option D is incorrect because brivaracetam's carboxylic acid metabolite does not cause nephrotoxicity and brivaracetam does not require renal function monitoring beyond standard clinical practice; dose adjustment for renal impairment is not required for brivaracetam, which is the opposite of levetiracetam.
Option E: Option E is incorrect because while hepatic function baseline testing is appropriate before starting brivaracetam given its hepatic metabolism, brivaracetam does not produce a hepatotoxic CYP2C19 intermediate metabolite; the concern with brivaracetam and hepatic disease is impaired drug clearance requiring dose adjustment, not active hepatotoxicity from a reactive metabolite.

4. A 22-year-old man with focal epilepsy has been on perampanel 8 mg/day at bedtime with good seizure control for six months. His dose is increased to 10 mg/day to address occasional breakthrough auras. Three weeks later his partner calls the neurology clinic reporting that he has become increasingly hostile, has made threatening statements to coworkers, and struck a wall in anger — behaviors entirely out of character. He denies any substance use. Which response is most appropriate?

A) Reassure the partner that these behavioral changes are unrelated to perampanel because psychiatric adverse effects from this drug only occur within the first two weeks of initiation; after six months of stable treatment, new behavioral symptoms indicate an independent psychiatric condition requiring referral to psychiatry before any medication change
B) Recognize this as a manifestation of perampanel's FDA boxed warning for serious psychiatric and behavioral reactions, which are dose-dependent and have increased after the dose increase to 10 mg/day; reduce the dose back to 8 mg/day, counsel the patient and partner that improvement will be gradual over 2 to 3 weeks given the long half-life, and monitor closely
C) Discontinue perampanel immediately and completely because the FDA boxed warning for homicidal ideation requires immediate cessation upon any sign of aggression; the long half-life means the drug will self-taper safely over several weeks and no formal dose reduction schedule is needed
D) Increase the perampanel dose further to 12 mg/day because breakthrough auras indicate subtherapeutic seizure control, and the behavioral symptoms likely reflect increased seizure activity causing postictal irritability rather than a drug adverse effect; higher doses will improve seizure control and secondarily resolve the behavioral symptoms
E) Add a selective serotonin reuptake inhibitor (SSRI) to manage the newly emerged aggression without reducing the perampanel dose, because maintaining seizure control is the clinical priority and SSRIs are first-line treatment for aggression in patients with epilepsy regardless of its pharmacological cause

ANSWER: B

Rationale:

This presentation is a textbook manifestation of perampanel's FDA boxed warning for serious psychiatric and behavioral reactions. The warning specifically identifies aggression, hostility, irritability, anger, and homicidal ideation as dose-dependent adverse effects that occur more frequently above 8 mg/day. The temporal relationship — behavioral change appearing approximately three weeks after a dose increase from 8 to 10 mg/day, consistent with perampanel's 2 to 3-week time to reach new steady state — strongly implicates the dose increase as the cause. The correct management is dose reduction back to 8 mg/day, which previously controlled seizures adequately. Because perampanel's half-life is 70 to 110 hours, plasma concentrations will fall gradually over 2 to 3 weeks after the dose reduction, and the partner must be counseled that behavioral improvement will be gradual rather than immediate. Close follow-up to confirm resolution and assess seizure control at the lower dose is appropriate.

Option A: Option A is incorrect because perampanel's psychiatric adverse effects are not restricted to the first two weeks of treatment — they are dose-dependent and can emerge or worsen any time the dose is increased; the three-week onset after a dose increase is consistent with the pharmacokinetic time to new steady state, not evidence of an unrelated psychiatric condition.
Option C: Option C is incorrect because immediate complete discontinuation is not required by the boxed warning or prescribing guidance; the recommended management for behavioral adverse effects is dose reduction, not abrupt cessation. Complete abrupt discontinuation risks seizure recurrence and is not necessary because the long half-life means gradual decline in drug levels follows any dose reduction.
Option D: Option D is incorrect because escalating the perampanel dose in the face of dose-dependent behavioral toxicity is contraindicated; the breakthrough auras that prompted the original dose increase must be reassessed, but increasing to 12 mg/day would worsen the very toxicity now manifesting.
Option E: Option E is incorrect because adding an SSRI to treat drug-induced aggression without addressing the causative pharmacological mechanism — perampanel dose — fails to correct the underlying problem and exposes the patient to additional medication; dose reduction is the appropriate primary intervention for dose-dependent perampanel behavioral toxicity.

5. A 74-year-old man with type 2 diabetes presents with painful diabetic peripheral neuropathy (DPN). His creatinine clearance (CrCl) is 35 mL/min. He is not on any other CNS-active medications. His internist asks whether gabapentin or pregabalin is preferred for this patient and what dose adjustment is needed. Which answer is correct?

A) Gabapentin is preferred because its non-linear saturable absorption provides a built-in dose ceiling that prevents toxic accumulation in elderly patients with reduced renal clearance; no dose adjustment is needed because the transporter saturation limits the maximum amount absorbed regardless of renal function
B) Either agent can be started at standard doses without adjustment because the degree of renal impairment at CrCl 35 mL/min is insufficient to cause clinically meaningful drug accumulation for either gabapentin or pregabalin; dose adjustment thresholds for both agents begin only at CrCl below 15 mL/min
C) Pregabalin is preferred and no dose adjustment is needed because pregabalin undergoes partial hepatic metabolism that compensates for reduced renal clearance; the hepatic component of elimination maintains adequate total clearance even at CrCl 35 mL/min, and standard doses are safe in this patient
D) Pregabalin is preferred over gabapentin because its linear pharmacokinetics allow more predictable dose titration; however, both drugs require dose reduction at this level of renal impairment since both are eliminated renally unchanged, and pregabalin dosing should be adjusted based on CrCl per prescribing guidance
E) Gabapentin is preferred in this elderly patient because it has a longer elimination half-life than pregabalin, allowing once-daily dosing that improves adherence; dose adjustment for renal impairment is required only for pregabalin since gabapentin's saturable absorption naturally limits systemic exposure

ANSWER: D

Rationale:

Both gabapentin and pregabalin are eliminated renally unchanged with no hepatic metabolic contribution, meaning that reduced renal function directly reduces their clearance and requires formal dose adjustment. At CrCl 35 mL/min — which falls in the moderately impaired range — both drugs require dose reduction per their prescribing information to prevent accumulation, which in elderly patients with reduced renal reserve can lead to sedation, dizziness, ataxia, and respiratory depression risk. Pregabalin is preferred over gabapentin in this patient because its linear pharmacokinetics with bioavailability exceeding 90% across the full dose range allow precise, predictable dose titration. Gabapentin's non-linear saturable absorption makes its dose-response relationship more difficult to predict, which is a disadvantage when careful titration is needed in an elderly patient with renal impairment. Pregabalin also requires only twice-daily dosing versus gabapentin's three-times-daily regimen, which aids adherence. Dose adjustment for pregabalin in patients with CrCl 30 to 60 mL/min involves starting at lower doses and limiting the maximum dose per the prescribing information table.

Option A: Option A is incorrect because gabapentin's saturable absorption is not a protective dose-ceiling mechanism in renal impairment; even the fraction that is absorbed accumulates when renal clearance is reduced, and the non-linear absorption creates additional unpredictability rather than safety. Dose adjustment is required.
Option B: Option B is incorrect because both agents require dose adjustment at CrCl 35 mL/min, not only below 15 mL/min; the threshold for pregabalin dose adjustment begins at CrCl below 60 mL/min and for gabapentin at CrCl below 60 mL/min as well, both well above this patient's level.
Option C: Option C is incorrect because neither pregabalin nor gabapentin undergoes hepatic metabolism; both are eliminated entirely by renal excretion unchanged, and there is no compensatory hepatic pathway in renal impairment.
Option E: Option E is incorrect because gabapentin requires three-times-daily rather than once-daily dosing due to its short elimination half-life and saturable absorption, and gabapentin's absorption non-linearity does not reduce the need for dose adjustment in renal impairment.

6. A 41-year-old woman with drug-resistant focal epilepsy was started on cenobamate three weeks ago following the mandatory slow titration schedule. She now presents with fever (38.9°C), facial edema, a diffuse maculopapular rash, cervical lymphadenopathy, and laboratory results showing eosinophilia (1,800 cells/mcL) and elevated liver enzymes (ALT 3x upper limit of normal). She is currently on cenobamate 25 mg/day and lacosamide. Which action is most appropriate?

A) Continue cenobamate at the current dose without escalation and add oral prednisone 1 mg/kg/day for 10 days to suppress the presumed hypersensitivity response, then resume the titration schedule once the rash and fever have resolved and eosinophilia has normalized
B) Reduce the cenobamate dose back to 12.5 mg/day and slow the titration further by extending each step to 4 weeks instead of 2, because the slow titration schedule was insufficiently gradual for this patient; continued slow exposure will allow immune tolerance to develop and prevent progression to full DRESS
C) Discontinue cenobamate immediately, because this presentation — fever, rash, facial edema, lymphadenopathy, eosinophilia, and elevated liver enzymes — is consistent with DRESS (drug reaction with eosinophilia and systemic symptoms), a potentially life-threatening hypersensitivity reaction requiring immediate drug cessation and specialist management
D) Continue cenobamate and obtain a skin biopsy before making any medication change, because the clinical presentation could represent a viral exanthem or an adverse reaction to lacosamide rather than cenobamate-associated DRESS; modifying the cenobamate regimen without biopsy confirmation risks unnecessarily losing a potentially effective anti-seizure drug
E) Switch from cenobamate to a structurally unrelated anti-seizure drug immediately but complete the current cenobamate dose today first, because abrupt mid-dose discontinuation of cenobamate causes a rebound increase in seizure frequency that is more dangerous than the observed hypersensitivity reaction in a patient with drug-resistant epilepsy

ANSWER: C

Rationale:

This presentation — fever, diffuse rash, facial edema, lymphadenopathy, eosinophilia, and hepatic enzyme elevation developing within weeks of cenobamate initiation — is the clinical syndrome of DRESS (drug reaction with eosinophilia and systemic symptoms). DRESS is a potentially life-threatening multiorgan hypersensitivity reaction. In cenobamate's early clinical program, DRESS occurred specifically under conditions of rapid titration, and the mandatory slow titration schedule was implemented to prevent it. When DRESS is suspected, the offending drug must be discontinued immediately — continuation or dose reduction is not an acceptable response, because DRESS can progress to involve multiple organ systems including liver, kidneys, lungs, and bone marrow. The patient requires immediate discontinuation of cenobamate, urgent specialist management (dermatology, possibly immunology), close monitoring of organ function, and consideration of systemic corticosteroids under specialist guidance.

Option A: Option A is incorrect because continuing cenobamate even at current dose while adding corticosteroids is not appropriate management for suspected DRESS; the causative drug must be stopped immediately, not maintained at the current dose with immunosuppression layered on top.
Option B: Option B is incorrect because dose reduction and further slowing of titration are not appropriate responses to an established DRESS presentation; once the hypersensitivity syndrome has developed, continued drug exposure at any dose perpetuates the reaction. The slow titration schedule is a prevention strategy, not a treatment strategy once DRESS has occurred.
Option D: Option D is incorrect because obtaining a skin biopsy before acting on a clinically clear DRESS presentation introduces dangerous delay; the clinical constellation of fever, rash, facial edema, lymphadenopathy, eosinophilia, and liver enzyme elevation in the context of recent cenobamate initiation is sufficient to mandate immediate drug discontinuation — biopsy results are not required before acting to protect the patient from a life-threatening reaction.
Option E: Option E is incorrect because completing the current dose before discontinuing is clinically unacceptable; in a suspected DRESS reaction, the drug is stopped immediately without completing any remaining portion of the daily dose, and seizure risk from abrupt cenobamate discontinuation is manageable and clearly outweighed by the risk of continued exposure in an evolving life-threatening hypersensitivity reaction.

7. A 26-year-old woman with a history of childhood absence epilepsy has been on ethosuximide 750 mg/day since age 9 and has been absence-seizure-free for 12 years. She is now 8 weeks pregnant. Her neurologist notes that ethosuximide does not cover generalized tonic-clonic seizures (GTCSs) and that some women with CAE experience new or recurrent GTCSs during pregnancy due to hormonal and sleep changes. The neurologist considers whether to add a second agent prophylactically. Which statement best guides decision-making about adding valproate in this context?

A) Valproate should be added immediately as standard of care because all pregnant women with a history of absence epilepsy require dual coverage for GTCSs throughout pregnancy, and the risk of an uncontrolled GTCS causing fetal hypoxia or trauma outweighs valproate's teratogenic risk at the low adjunctive doses that would be used alongside ethosuximide
B) Valproate should be added because it is the only broad-spectrum anti-seizure drug that covers both absence seizures and GTCSs with established efficacy, and teratogenicity concerns apply only during the first trimester organogenesis period which has already largely passed at 8 weeks gestation
C) Valproate should be added with high-dose folic acid supplementation, which has been demonstrated in randomized controlled trials to fully neutralize valproate's teratogenic effects when started before 10 weeks gestation, making valproate safe to initiate in the second month of pregnancy
D) Ethosuximide should be discontinued immediately and replaced with lamotrigine monotherapy, because lamotrigine is the safest anti-seizure drug in pregnancy and covers both absence seizures and GTCSs with a teratogenic profile superior to all other options including ethosuximide
E) Valproate's teratogenic risk — including major congenital malformations, neural tube defects, and cognitive impairment in exposed offspring — is among the highest of any anti-seizure drug and its use in pregnancy requires careful individualized risk-benefit analysis; prophylactic addition is not automatically warranted in a patient who has been GTCS-free for years, and lamotrigine represents a lower-teratogenicity alternative with broad-spectrum coverage if an additional agent is genuinely needed

ANSWER: E

Rationale:

Valproate carries one of the highest teratogenic risks among anti-seizure drugs, including dose-dependent rates of major congenital malformations (approximately 6 to 10% at standard doses versus 2 to 3% background), neural tube defects, and — critically — dose-dependent cognitive impairment and autism spectrum disorder in exposed children, effects that persist after birth regardless of malformation status. These risks are not restricted to any single trimester; cognitive impairment from in-utero valproate exposure occurs throughout fetal brain development, which continues well beyond the first trimester. High-dose folic acid reduces neural tube defect risk but does not eliminate the cognitive teratogenicity. In a patient who has been GTCS-free for 12 years and whose primary epilepsy syndrome (CAE) often remits by adulthood, prophylactic addition of valproate is not automatically warranted without evidence of current GTCS risk. If broad-spectrum coverage is genuinely needed, lamotrigine has a substantially lower teratogenic profile than valproate, though with lower absence seizure efficacy. The decision requires individualized risk-benefit analysis, shared decision-making, and specialist input — not automatic valproate addition.

Option A: Option A is incorrect because prophylactic valproate addition is not standard of care for all pregnant women with a history of CAE; the decision requires individualized assessment and valproate's teratogenic burden is substantial enough that it cannot be dismissed simply by arguing seizure risk versus drug risk in the abstract.
Option B: Option B is incorrect on multiple grounds: teratogenicity concerns extend throughout pregnancy (fetal brain development continues into the third trimester), and the first trimester organogenesis period is not largely over at 8 weeks — it extends through approximately 10 to 12 weeks.
Option C: Option C is incorrect because high-dose folic acid has not been demonstrated in randomized trials to fully neutralize valproate's teratogenic effects; it reduces but does not eliminate neural tube defect risk and does not prevent valproate's cognitive teratogenicity.
Option D: Option D is incorrect because lamotrigine does not reliably cover absence seizures — in the CAE trial it had substantially lower seizure-freedom rates for absence than ethosuximide or valproate — and abruptly discontinuing ethosuximide in a patient who has been well controlled for 12 years poses unnecessary seizure recurrence risk.

8. A 31-year-old man with focal epilepsy has been seizure-free on perampanel 6 mg/day for 14 months. He is newly diagnosed with trigeminal neuralgia and his pain specialist starts carbamazepine 200 mg three times daily. Six weeks later he reports three breakthrough focal seizures — his first in over a year. A perampanel plasma level is obtained and is 38% lower than his last documented level before carbamazepine was started. Which explanation and management plan are correct?

A) Carbamazepine has induced CYP3A4, the primary enzyme responsible for perampanel metabolism; CYP3A4 induction has accelerated perampanel clearance, reducing plasma concentrations by approximately 38% and causing breakthrough seizures; the perampanel dose should be increased — prescribing guidance indicates that dose increases of approximately 2-fold may be needed when strong CYP3A4 inducers are added
B) Carbamazepine has inhibited the P-glycoprotein efflux transporter at the blood-brain barrier, reducing perampanel CNS penetration while leaving plasma levels relatively intact; the plasma level measurement therefore underestimates the degree of CNS drug reduction, and the perampanel dose should be doubled immediately to restore therapeutic brain concentrations
C) Carbamazepine has displaced perampanel from plasma protein binding sites, reducing total perampanel concentration while free perampanel is unchanged; the lower total level does not represent reduced pharmacological activity, and no dose change is needed — free perampanel measurement will confirm therapeutic free drug concentrations
D) The breakthrough seizures are unrelated to the perampanel level change; the 38% reduction is within normal pharmacokinetic variability for perampanel and does not represent a clinically significant interaction — the seizures are more likely explained by sleep disruption from trigeminal neuralgia pain, and gabapentin should be substituted for carbamazepine to treat the pain without affecting perampanel levels
E) Carbamazepine has inhibited CYP3A4 through competitive substrate inhibition, transiently reducing perampanel metabolism; the 38% level reduction will resolve spontaneously as CYP3A4 adapts to the additional substrate load over 4 to 6 weeks, and no perampanel dose change is needed at this time

ANSWER: A

Rationale:

Perampanel is metabolized primarily by CYP3A4. Carbamazepine is one of the most potent CYP3A4 inducers in clinical use, upregulating CYP3A4 expression through pregnane X receptor activation and substantially accelerating the clearance of CYP3A4 substrates. The prescribing information for perampanel specifically identifies carbamazepine, phenytoin, and oxcarbazepine as strong CYP3A4 inducers that reduce perampanel plasma concentrations by approximately 50 to 67%. In this patient, a 38% reduction consistent with the expected interaction has coincided with three breakthrough seizures after 14 months of seizure freedom. The correct management is to increase the perampanel dose — label guidance indicates that patients on strong CYP3A4 inducers may need approximately double the dose to achieve plasma concentrations equivalent to those achieved without the inducer. Coordination with the pain specialist to consider whether carbamazepine can be replaced with a non-inducing agent for the trigeminal neuralgia is also reasonable but does not address the immediate seizure risk.

Option B: Option B is incorrect because carbamazepine is not a P-glycoprotein inhibitor; it is a CYP3A4 and P-gp inducer — induction of P-gp would increase efflux and reduce CNS penetration rather than inhibit efflux. The measured plasma level reduction accurately reflects reduced systemic drug exposure from accelerated CYP3A4-mediated clearance.
Option C: Option C is incorrect because perampanel is approximately 95% protein-bound and carbamazepine-induced protein displacement is not an established mechanism for this interaction; the reduced total level reflects reduced drug availability from metabolic induction, not a shift in protein binding. Furthermore, at 95% protein binding, a displacement interaction would need to dramatically shift the bound-to-free ratio to account for a 38% total level change.
Option D: Option D is incorrect because a 38% reduction in perampanel levels is a clinically significant pharmacokinetic interaction that directly correlates with breakthrough seizures; dismissing it as variability and attributing seizures to sleep disruption ignores the clear mechanistic explanation.
Option E: Option E is incorrect because carbamazepine is a CYP3A4 inducer, not a competitive inhibitor; induction increases total CYP3A4 enzyme expression rather than competing for substrate binding, and the effect is persistent rather than transient — it does not spontaneously resolve as the enzyme adapts.

9. A 38-year-old woman with fibromyalgia and a documented history of opioid use disorder (OUD) in sustained remission on buprenorphine-naloxone maintenance therapy is referred for pain management. Her rheumatologist proposes starting pregabalin for fibromyalgia. Which statement best characterizes the prescribing considerations specific to this patient?

A) Pregabalin is contraindicated in patients with a history of opioid use disorder because its Schedule II controlled substance status prohibits co-prescription with buprenorphine-naloxone under federal REMS regulations; an unscheduled alternative such as duloxetine should be prescribed instead
B) Pregabalin has recognized abuse potential and carries Schedule V controlled substance status in the United States; in patients with opioid use disorder, concurrent use with buprenorphine-naloxone introduces meaningful risk of enhanced CNS depression and respiratory depression because both drugs suppress respiratory drive through independent mechanisms, and this combination requires careful patient counseling, monitoring, and risk-benefit assessment
C) Pregabalin is the safest option for this patient precisely because of its Schedule V status — lower scheduling reflects lower abuse potential than buprenorphine, and the combination of a Schedule V drug with a Schedule III drug (buprenorphine) carries no additional regulatory or clinical monitoring requirements compared to either drug prescribed alone
D) Pregabalin should be avoided in this patient solely because of its non-linear absorption kinetics, which make dose-response unpredictable in patients with opioid use disorder due to altered gastrointestinal motility from chronic opioid exposure; gabapentin with its three-times-daily schedule avoids this unpredictability and is preferred
E) Pregabalin is appropriate for this patient without special precautions because buprenorphine-naloxone is a partial mu-opioid agonist whose ceiling effect on respiratory depression prevents additive respiratory suppression with any concurrently prescribed drug; the partial agonist ceiling eliminates the respiratory risk that would apply if the patient were on a full mu-agonist opioid

ANSWER: B

Rationale:

Pregabalin is a Schedule V controlled substance in the United States, reflecting recognized abuse and misuse potential. In patients with opioid use disorder — even those in sustained remission on medication-assisted treatment — gabapentinoids carry heightened risk for several reasons. First, pregabalin enhances sedation and euphoria when combined with opioids or partial opioid agonists, which can be reinforcing and threaten remission. Second, both pregabalin and buprenorphine suppress respiratory drive through independent mechanisms — pregabalin reduces presynaptic calcium influx in brainstem respiratory neurons via alpha-2-delta subunit binding, while buprenorphine produces mu-opioid receptor-mediated respiratory depression — and their combination can produce additive respiratory suppression that exceeds what either agent produces alone, even with buprenorphine's partial agonist ceiling effect. Third, gabapentinoid misuse in patients with OUD is specifically identified as a clinical concern in substance use disorder literature. The prescribing decision requires explicit patient counseling about these risks, careful monitoring, and consideration of non-gabapentinoid alternatives such as duloxetine or low-dose tricyclic antidepressants for fibromyalgia.

Option A: Option A is incorrect because pregabalin is Schedule V, not Schedule II, and there is no federal REMS prohibition on co-prescribing pregabalin with buprenorphine-naloxone; the combination requires clinical judgment and monitoring but is not federally prohibited.
Option C: Option C is incorrect because lower scheduling does not eliminate clinical monitoring requirements when combining CNS depressants — Schedule V designation reflects comparatively lower but still recognized abuse potential, and the clinical risks of the combination are real regardless of relative scheduling level.
Option D: Option D is incorrect because pregabalin has linear rather than non-linear absorption; it is gabapentin that has saturable non-linear absorption. The premise of this option reverses the correct pharmacokinetic characteristic of these two agents.
Option E: Option E is incorrect because buprenorphine's partial agonist ceiling effect reduces but does not fully eliminate its respiratory depressant potential, and the ceiling applies to buprenorphine's own contribution — it does not create a global barrier to additive respiratory depression when other CNS depressants with independent mechanisms are added concurrently.

10. A neurology fellow is evaluating a 15-year-old girl referred for frequent absence seizures. Video-EEG confirms generalized 3.5 to 4-Hz spike-and-wave discharges consistent with juvenile absence epilepsy (JAE). Her mother reports that she also has brief myoclonic jerks on awakening and one witnessed generalized tonic-clonic seizure six months ago. The fellow proposes starting ethosuximide because the absence seizures are the most frequent and bothersome symptom. Which response best evaluates this proposal?

A) The proposal is appropriate because ethosuximide's T-type calcium channel blockade specifically targets the thalamo-cortical oscillation underlying all generalized spike-and-wave discharges regardless of the syndromic subtype; since the EEG shows generalized discharges, ethosuximide will be equally effective for the absence, myoclonic, and tonic-clonic components of this patient's syndrome
B) The proposal is appropriate for the absence seizures and the myoclonic jerks but not for the tonic-clonic seizures; ethosuximide should be started with a benzodiazepine rescue medication prescribed separately for any future GTCS events, as this combination adequately covers all three seizure types present in this patient
C) The proposal is appropriate because juvenile absence epilepsy is a benign self-limited syndrome that always remits by age 18; ethosuximide covers the most symptomatic seizure type during the active phase, and no further treatment planning is needed for the myoclonic and tonic-clonic components since they will resolve on their own before adulthood
D) The proposal is inappropriate because this patient has juvenile absence epilepsy with concurrent myoclonic jerks and a recent GTCS — a syndrome requiring broad-spectrum coverage; ethosuximide covers only absence seizures and has no efficacy against myoclonic or tonic-clonic seizures, making valproate or levetiracetam a more appropriate monotherapy choice for this multi-seizure-type syndrome
E) The proposal is appropriate provided the ethosuximide dose is titrated to the upper end of the therapeutic range (plasma level 80 to 100 mcg/mL), because higher concentrations of ethosuximide produce sufficient suppression of thalamo-cortical excitability to also prevent the myoclonic and tonic-clonic seizures that share the same thalamo-cortical circuit with absence seizures in generalized epilepsy syndromes

ANSWER: D

Rationale:

This patient has juvenile absence epilepsy (JAE) with multiple seizure types — absence seizures, myoclonic jerks on awakening, and a recent GTCS. This is not pure absence epilepsy; it is a generalized epilepsy syndrome with multiple seizure types. Ethosuximide's anti-seizure activity is mechanistically restricted to absence seizures driven by T-type calcium channel-dependent thalamo-cortical oscillation. It has no established efficacy against myoclonic seizures or generalized tonic-clonic seizures, which are generated through different mechanisms. Starting ethosuximide in a patient with all three seizure types would address only one component while leaving myoclonic and tonic-clonic seizures untreated. For a multi-seizure-type generalized epilepsy syndrome in an adolescent, valproate has historically been the broad-spectrum first-line agent covering all three seizure types; levetiracetam is an alternative with coverage for myoclonic and GTCS components. The choice requires accounting for valproate's adverse effect and teratogenicity profile in an adolescent girl. Ethosuximide monotherapy is reserved for pure absence epilepsy without other seizure types.

Option A: Option A is incorrect because ethosuximide does not have efficacy against all seizure types associated with generalized spike-and-wave discharges; the presence of generalized EEG discharges does not confer equal responsiveness across all anti-seizure mechanisms. Myoclonic and tonic-clonic seizures are not driven by the T-type channel oscillatory mechanism and do not respond to T-type channel blockade.
Option B: Option B is incorrect because ethosuximide also lacks efficacy against myoclonic jerks, not only tonic-clonic seizures; treating only the tonic-clonic component with rescue medication while leaving myoclonic and absence seizures managed with separate drugs is not an appropriate monotherapy strategy for this syndrome.
Option C: Option C is incorrect because juvenile absence epilepsy does not universally remit by age 18; unlike childhood absence epilepsy, JAE often persists into adulthood, and the presence of myoclonic jerks and a GTCS indicates a syndromic profile that requires comprehensive treatment planning.
Option E: Option E is incorrect because ethosuximide's lack of efficacy in myoclonic and tonic-clonic seizures is mechanistic and dose-independent; higher plasma concentrations do not extend its pharmacological activity to seizure types that do not depend on T-type calcium channel thalamic oscillation.

11. A 52-year-old man with drug-resistant focal epilepsy has been well-controlled on brivaracetam 100 mg twice daily for two years. He presents with jaundice, fatigue, and right upper quadrant discomfort. Laboratory results reveal ALT 8x the upper limit of normal, bilirubin 4.2 mg/dL, and INR 1.8, consistent with significant hepatic dysfunction. His creatinine is 0.9 mg/dL and CrCl is 88 mL/min. The hepatologist diagnoses alcohol-related hepatitis; the patient acknowledges recent heavy alcohol use. Which statement best guides management of his brivaracetam dosing?

A) Brivaracetam dose does not require adjustment because it is primarily renally eliminated, like levetiracetam; his normal creatinine and CrCl of 88 mL/min confirm adequate drug clearance, and hepatic function is not relevant to brivaracetam's elimination pathway
B) Brivaracetam should be discontinued immediately because hepatic disease is an absolute contraindication to all anti-seizure drugs that undergo any degree of hepatic metabolism; the patient should be bridged with intravenous lorazepam until hepatic function normalizes and brivaracetam can be safely restarted
C) Brivaracetam requires dose reduction in this patient because it undergoes hepatic metabolism as its primary elimination pathway — primarily via amidase hydrolysis — and significant hepatic dysfunction will impair its clearance; prescribing guidance recommends dose reduction in moderate to severe hepatic impairment, and his current presentation with elevated INR and bilirubin represents at least moderate hepatic dysfunction
D) Brivaracetam dose should be increased in this patient because hepatic inflammation upregulates CYP2C19 enzyme expression during the acute phase response, accelerating brivaracetam metabolism and reducing plasma concentrations below therapeutic levels; a temporary 50% dose increase will compensate for the increased CYP2C19 activity
E) Brivaracetam dose does not require adjustment because its carboxylic acid metabolite — not the parent drug — is the compound that requires hepatic processing, and the parent drug itself is cleared by non-hepatic pathways; metabolite accumulation is clinically inert and does not affect therapeutic drug monitoring of parent brivaracetam

ANSWER: C

Rationale:

Brivaracetam is metabolized primarily by amidase-mediated hydrolysis to an inactive carboxylic acid metabolite, with a secondary CYP2C19 contribution. Because hepatic metabolism is the primary elimination pathway, significant hepatic dysfunction directly impairs brivaracetam clearance and leads to drug accumulation at standard doses. This patient's presentation — ALT 8 times the upper limit of normal, hyperbilirubinemia, and elevated INR reflecting impaired synthetic function — represents significant hepatic dysfunction, likely corresponding to at least moderate severity (Child-Pugh B equivalent findings). Brivaracetam prescribing guidance specifically recommends dose reduction in moderate and severe hepatic impairment. This clinical scenario — brivaracetam toxicity risk from impaired hepatic clearance in a patient with acute hepatic dysfunction — illustrates the practical importance of knowing that brivaracetam, unlike levetiracetam, requires hepatic rather than renal dose adjustment. His normal renal function is irrelevant to brivaracetam clearance because renal elimination is not the primary route.

Option A: Option A is incorrect because brivaracetam is not primarily renally eliminated; unlike levetiracetam, it undergoes significant hepatic metabolism and requires dose adjustment based on hepatic function, not renal function.
Option B: Option B is incorrect because hepatic disease is not an absolute contraindication to all hepatically metabolized anti-seizure drugs; dose adjustment is the appropriate response to impaired clearance, and abrupt discontinuation of brivaracetam in a patient with drug-resistant epilepsy without a safe transition plan risks seizure recurrence.
Option D: Option D is incorrect because hepatic inflammation does not upregulate CYP2C19 in a clinically meaningful way that accelerates drug metabolism; acute hepatitis impairs rather than enhances hepatic metabolic capacity, and a dose increase in the setting of impaired clearance would worsen drug accumulation.
Option E: Option E is incorrect because amidase-mediated hydrolysis of brivaracetam to its carboxylic acid metabolite occurs in the liver, and significant hepatic dysfunction impairs this primary metabolic step; the premise that parent drug clearance is non-hepatic is factually incorrect.